Building on a relentless commitment to customer service and innovation, Beckman Coulter Life Sciences debuts a powerful new interactive customer resource with the launch of its Digital Campus. The 3D platform provides greater access to the company’s resources regardless of physical location and allows users to control their experience including the chance to get up close and personal with products and experts.

Despite a couple of notable ‘firsts’ for European public biotech financing, biotech’s COVID-19 bubble may be about to burst. Virus fears pushed both private and public investors toward biotech, but vaccination successes have changed the sentiment. Now, it seems there are simply too many biotech companies, especially in Europe.

Lund-based Immunovia will need a new CEO, because Patrik Dahlen wants to leave the diagnostics company for personal reasons.

The start-up competition @AMR conference supported by INCATE has started. Early-stage ventures fighting drug resistant bacterial infections in the therapeutics or diagnostics area interested to be on stage are invited to apply now! 

Quell Therapeutics has raised a whopping US$156m from a prestigious investor group in an oversubscribed Series B financing. With the funds, the British biotech wants to hasten its CAR-Treg cell therapy candidate on its way to the clinic.

Vaccibody rebrands as Nykode Therapeutics and teams up with Regeneron in a vaccine deal potentially worth US$925m.

Dr Nicolas Gaudenzio has been started at the beginning of November as Chief Scientific Officer of Genoskin.

The European Commission has inked the pre-purchase agreement over Valneva’s inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.

Swiss Vifor Pharma is shelling out more than €375m for Mallorca-based Sanifit, a clinical-stage cardio-renal biopharmaceutical company with a single compound in development.

Novo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.